Who we are

We see a future where sequencing generates more information from DNA and is achievable at far lower costs, bringing closer the day when advanced medicines, diagnostics and personalized treatments become a reality for all.

Cambridge Epigenetix (CEGX) is a life sciences tools and analytics company that has created a technology platform delivering step changes in both the type of information that can be generated from DNA and the cost at which it is gathered.

Our Team


Gail Marcus

Executive Chair

Professor Sir Shankar Balasubramanian FRS


Professor Joanna Holbrook

Senior Vice President of Research

Fiona Stewart

Chief Financial Officer

Manuela Morgan

Head of Human Resources

Scientific Advisors

Professor Sir Shankar Balasubramanian FRS


Professor Wolf Reik

Head of the Epigenetics Programme, Babraham Institute

Professor Anjana Rao

Head of the Division of Signalling and Gene Expression, La Jolla Institute

Professor Mark Dawson

Group Leader of the Cancer Epigenetics Laboratory, Peter MacCallum Cancer Centre

Rahul Kohli

Associate Professor of Medicine and Biochemistry & Biophysics, Penn Epigenetics Institute, University of Pennsylvania (UPenn)


Gail Marcus

Executive Chair

Dr. Bobby Yerramilli-Rao


Professor Sir Shankar Balasubramanian FRS


Tom Hulme

General Partner, GV

Alice Newcombe-Ellis

Managing Partner, Ahren Innovation Capital

Somu Subramaniam

Managing Partner, New Science Ventures

Roelof F. Botha

Managing Partner, Sequoia Capital





New Science Ventures

Sequoia Capital